SARS-CoV-2 是否经输血传播？
Is SARS-CoV-2 transfusion transmitted?
机构信息
Mississippi Valley Regional Blood Center, Davenport, IA, USA.
Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
出版信息
Transfusion. 2020 Jun;60(6):1111-1114. doi: 10.1111/trf.15831.
Abstract
See article on page 1119–1122, in this issue
摘要
见本期第 1119-1122 页文章
相似文献
1
Is SARS-CoV-2 transfusion transmitted?
Transfusion. 2020 Jun;60(6):1111-1114. doi: 10.1111/trf.15831.
2
Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).
Travel Med Infect Dis. 2020 May-Jun;35:101608. doi: 10.1016/j.tmaid.2020.101608. Epub 2020 Feb 27.
3
From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.
Fa Yi Xue Za Zhi. 2020 Feb;36(1):1-3. doi: 10.12116/j.issn.1004-5619.2020.01.001. Epub 2020 Feb 25.
4
A cluster of pneumonia associated with the SARS-Cov-2 outside of Wuhan related to a house-warming banquet.
J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.034. Epub 2020 Apr 10.
5
Challenges and issues of SARS-CoV-2 pool testing.
Lancet Infect Dis. 2020 Nov;20(11):1233-1234. doi: 10.1016/S1473-3099(20)30467-9. Epub 2020 Jul 14.
6
Challenges and issues of SARS-CoV-2 pool testing.
Lancet Infect Dis. 2020 Nov;20(11):1233. doi: 10.1016/S1473-3099(20)30463-1. Epub 2020 Jul 14.
7
Challenges and issues of SARS-CoV-2 pool testing.
Lancet Infect Dis. 2020 Nov;20(11):1232-1233. doi: 10.1016/S1473-3099(20)30516-8. Epub 2020 Jul 14.
8
Duration of SARS-CoV-2 viral RNA in asymptomatic carriers.
Crit Care. 2020 May 24;24(1):245. doi: 10.1186/s13054-020-02952-0.
9
Duration for carrying SARS-CoV-2 in COVID-19 patients.
J Infect. 2020 Jul;81(1):e78-e79. doi: 10.1016/j.jinf.2020.03.053. Epub 2020 Apr 10.
10
SARS-CoV, Mers-CoV and COVID-19: what differences from a dermatological viewpoint?
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e581-e582. doi: 10.1111/jdv.16738. Epub 2020 Jul 2.
引用本文的文献
1
Characteristics of HPC(A) product obtained from a donor with SARS-CoV-2 infection and outcome of autologous transplant.
Stem Cell Res Ther. 2024 Aug 13;15(1):251. doi: 10.1186/s13287-024-03872-4.
2
Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases.
Transfus Med Rev. 2023 Oct;37(4):150769. doi: 10.1016/j.tmrv.2023.150769. Epub 2023 Oct 4.
3
Lessons Learned from the COVID-19 Pandemic and How Blood Operators Can Prepare for the Next Pandemic.
Viruses. 2022 Sep 27;14(10):2126. doi: 10.3390/v14102126.
4
Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review.
Transfus Med Hemother. 2022 Mar 23;5(4):1-11. doi: 10.1159/000522264.
5
SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network.
Blood Transfus. 2022 Sep;20(5):362-373. doi: 10.2450/2022.0266-21. Epub 2022 Jan 21.
6
SARS-CoV-2 and blood donations in Portugal, June-July 2020.
J Med Virol. 2022 Jan;94(1):42-43. doi: 10.1002/jmv.27353. Epub 2021 Sep 27.
7
SARS-COV-2: is it a risk for blood transfusion?
Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):100-103. doi: 10.1016/j.htct.2021.08.001. Epub 2021 Sep 1.
8
Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.
Transfus Med Rev. 2021 Jul;35(3):1-7. doi: 10.1016/j.tmrv.2021.07.001. Epub 2021 Jul 30.
9
Detection of antibodies against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins produced from plasma collected in Italy during the pandemic.
Blood Transfus. 2022 May;20(3):198-205. doi: 10.2450/2021.0055-21. Epub 2021 May 27.
10
SARS-CoV-2 routes of transmission and recommendations for preventing acquisition: joint British Infection Association (BIA), Healthcare Infection Society (HIS), Infection Prevention Society (IPS) and Royal College of Pathologists (RCPath) guidance.
J Hosp Infect. 2021 Aug;114:79-103. doi: 10.1016/j.jhin.2021.04.027. Epub 2021 May 1.
本文引用的文献
1
SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission.
Transfusion. 2020 Jun;60(6):1119-1122. doi: 10.1111/trf.15841. Epub 2020 May 27.
2
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
3
Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations.
Emerg Infect Dis. 2020 Jul;26(7):1631-1633. doi: 10.3201/eid2607.200839. Epub 2020 Jun 21.
4
Post-donation COVID-19 identification in blood donors.
Vox Sang. 2020 Nov;115(8):601-602. doi: 10.1111/vox.12925. Epub 2020 Apr 21.
5
Virological assessment of hospitalized patients with COVID-2019.
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
6
Detection of SARS-CoV-2 in Different Types of Clinical Specimens.
JAMA. 2020 May 12;323(18):1843-1844. doi: 10.1001/jama.2020.3786.
7
Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.
Emerg Microbes Infect. 2020 Feb 17;9(1):386-389. doi: 10.1080/22221751.2020.1729071. eCollection 2020.
8
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
9
Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light.
Transfusion. 2018 Jan;58(1):52-59. doi: 10.1111/trf.14422. Epub 2017 Dec 14.
10
Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment.
Transfusion. 2016 Dec;56(12):2948-2952. doi: 10.1111/trf.13860. Epub 2016 Nov 2.
Zotero 插件